Genetic Variation Affects Smoking Cessation Treatment
New study published in Biological Psychiatry
Philadelphia, PA, September 20, 2007 – Mark Twain boasted that it was easy to quit smoking because he did it every day. We now may have the beginnings of understanding why some people find it so difficult to stop smoking even when they are in treatment for this problem. According to statistics provided by the Centers for Disease Control and Prevention (CDC), tobacco use is the leading preventable cause of death in the United States, and it is the second major cause of death in the world according to the World Health Organization (WHO). An estimated 20.9% of all US adults smoke, and even with a strong desire to quit, most find it exceptionally difficult. A new study being published in the September 15th issue of Biological Psychiatry reports that genetic variation in a particular enzyme affects the success rates of treatment with bupropion, an anti-smoking drug.
Lee and colleagues performed CYP2B6 genotyping on smoking individuals, a gene that is known to be highly variable and whose enzyme metabolizes both bupropion and nicotine. Participants were then provided with either placebo or bupropion treatment for ten weeks. The authors discovered that individuals with the CYP2B6*6 allele of the gene benefited from bupropion treatment and maintained abstinence longer while doing poorly on placebo, with a 32.5% abstinent rate vs. 14.3%, respectively. In contrast, those in the CYP2B6*1 group did well on both bupropion and placebo, with similar abstinence rates at the end of treatment and after a six month follow-up.
Rachel Tyndale, M.Sc., Ph.D., one of the authors on this study, comments, "This first study, while requiring replication, identifies a very common genetic variant that appears to affect smoking cessation treatment outcome." This variant is present in 25-50% of people, thus affecting a large portion of the population.
John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, adds his thoughts about this exciting new data: "We look forward to the era of personalized medicine, when doctors are able to use genetic information about their patients to guide treatment. We are not ready to use this information in clinical practice, but this study provides us with a good example of the type of information that might, some day, guide the treatment for smoking."
# # #
Notes to Editors:
The article is "CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial" by Anna M. Lee, Christopher Jepson, Ewa Hoffmann, Leonard Epstein, Larry W. Hawk, Caryn Lerman and Rachel F. Tyndale. Drs. Lee, Hoffmann, and Tyndale are affiliated with the Centre for Addiction and Mental Health and the Department of Pharmacology at The University of Toronto in Ontario, Canada. Drs. Jepson and Lerman are with the Department of Psychiatry at Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. Dr. Epstein is with the Department of Pediatrics, while Dr. Hawk is with the Department of Psychology at The University of Buffalo, State University of New York, Buffalo, New York. This article appears in Biological Psychiatry, Volume 62, Issue 6 (September 15, 2007), published by Elsevier.
This work was supported by a Canadian Tobacco Control Research Initiative student grant 16803 (AML), Canadian Institute of Health Research (CIHR) Tobacco Use in Special Populations Fellowship (AML), grants from the National Cancer Institute and National Institutes on Drug Abuse, P5084718, RO1 CA63562 (CL) and DA020830 (RFT, CL), CIHR grant MOP53248 (RFT), and a Canada Research Chair in Pharmacogenetics (RFT). Study medication was provided at no cost by GlaxoSmithKline.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at (215) 239-3674 or email@example.com to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry is ranked 4th out of the 95 Psychiatry titles and 16th out of 199 Neurosciences titles on the 2006 ISI Journal Citations Reports® published by Thomson Scientific.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+1 215 239 3674